Ascendis Pharma A/S
Ascendis Pharma A/S (Denmark) is linked to 1 FDA-registered manufacturing site. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Ascendis Pharma A/S: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/ascendis-pharma-a-s
Overview
Ascendis Pharma A/S is a biopharmaceutical company that leverages its proprietary TransCon technology to address unmet medical needs in endocrinology and oncology. The company's innovative approach aims to generate best-in-class therapies, providing sustained release of the active compound.
Core services & business areas
Therapeutic areas
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to Ascendis Pharma A/S, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Ascendis Pharma A/S in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this Ascendis Pharma A/S?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.